The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.

How is TNKase administered?

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.

How Was TNKase approved?

The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.

How Common Are These Strokes?

In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.

TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."

What Are The Symptoms Of Ischemic Strokes?

Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.

Other symptoms include:

• Loss of coordination or clumsiness
• Blurry vision or double vision
• Dizziness or vertigo
• Nausea and vomiting
• Neck stiffness
• Mood swings or sudden personality changes
• Confusion or agitation
• Seizures
• Memory loss (amnesia)
• Headaches which are sudden and severe
• Passing out or fainting
• Coma

Are There Any Warning Signs?

While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.

The child death rate in the United States has increased significantly over the years. A new study published in the New England Journal of Medicine, showed that the child and adolescent death rate in the US rose to 6.6 percent between 2020 and 2023.

Caroline Raymond-King, an emergency medicine resident at Yale School of Medicine, and her colleagues analyzed data from three full years, from 2018 to 2023. The team found out the rates, trends, and massive issues behind this spike in deaths in the age bracket between 1 and 19 years old.

What Are The Causes Behind These Rising Death Rates?

• firearms,
• car accidents,
• poisoning.

Even the lead researcher, Raymond-King herself, was inspired to work on this project because she witnessed the massive surge of injured children and adolescents in the emergency department.

The study has seen that the leading cause of death in the discussed age bracket is firearm incidents. Since 2020, it has remained the major reason for death among youth. In 2020 itself, the gun-related incidents surpassed motor vehicle crashes as the leading cause of death for children in the United States. Not only that, but the firearm-related incidents have also increased their share of the mortality rate of children. Between 2020 and 2023, child deaths due to firearms increased by 3.9 percent.

Along with the gun-related deaths, the other major issues, like motor vehicle crashes and drug poisoning deaths, have also seen an alarming upward trend. Between 2020 and 2023, the deaths related to road accidents rose by 8.6 percent. On the other hand, the mortality rate due to drug poisoning has gone up to 12.7 percent.

Other than those three major causes, there are other reasons behind these rising death rates, as follows: cancer, suffocation, congenital anomalies, drowning, heart disease, and fire.

How To Deal With This Hike In Child Death Rate?

Raymond-King's study has worked intensively on the ways to prevent these untimely deaths in children and adolescents. They have shared their views on the possible precautions to reduce risks.

• First and foremost, if there are guns in your house, then you must store them in a locked and secure place. The ammunition should not be alongside the guns. The medication should also be kept far away from children's reach.

• Secondly, in the time period of the research, the deaths related to influenza, pneumonia, and COVID-19 prove the importance of vaccination. Thus, the necessary vaccination is a must for the safety of your children.

• The study also gives great emphasis on mental health. Thus, connecting young people with psychiatric care can be an impactful decision.

Sexually transmitted infections (STIs) such as gonorrhea and syphilis have hit record levels in Europe in over a decade, according to new data from the European Centre for Disease Prevention and Control (ECDC).

As per the agency’s latest Annual Epidemiological Reports, there has been a sharp surge in bacterial STIs across Europe. It showed that the notifications of gonorrhea and syphilis, alongside congenital syphilis in 2024, reached their highest levels in over a decade, reflecting sustained transmission across multiple countries.

The ECDC blamed the "widening gaps in testing and prevention” behind the spike in STIs. It also called for urgent targeted action to prevent further spread, including among women of reproductive age.

STI Cases Continue To Climb

The data for 2024 show that:

• gonorrhea cases reached 106,331, representing a 303 per cent increase since 2015.
• syphilis cases more than doubled over the same period to 45,577 cases.
• chlamydia remains the most frequently reported STI with 213,443 cases.
• lymphogranuloma venereum (LGV) also continued to see ongoing transmission, with 3,490 reported cases.

Bruno Ciancio, Head of Unit, Directly Transmitted and Vaccine-Preventable Diseases, said that left untreated, “these infections can cause severe complications, such as chronic pain and infertility and, in the case of syphilis, problems with the heart or nervous system”.

“Most distressingly, between 2023 and 2024, we have seen a near doubling of congenital syphilis, where infections pass directly to newborns, leading to potentially lifelong complications,” Ciancio added.

Disproportionately Affected Groups

Transmission trends vary significantly across different population groups, the ECDC said.

Men who have sex with men remain the most disproportionately affected group, with the steepest long-term increases in gonorrhea and syphilis.

Among heterosexual populations, syphilis is rising, particularly among women of reproductive age, the consequences of which are a near doubling of congenital syphilis cases from 78 in 2023 to 140 in 2024 across 14 countries reporting data.

ECDC Calls For Urgent Action

Reversing increasing trends in STI cases requires accessible prevention services, easier access to testing, faster treatment, and stronger partner notification to stop onward transmission.

The ECDC urged public health authorities to urgently update national STI strategies and strengthen surveillance systems to better monitor the impact of prevention efforts.

“Protecting your sexual health remains straightforward. Use condoms with new or multiple partners, and get tested if you have symptoms, such as pain, discharge, or an ulcer,” Ciancio said.

UK Rolls Out Gonorrhea Vaccine

In the wake of increasing gonorrhea cases, the UK in 2025 rolled out a new vaccine. The vaccine, available at sexual health clinics across England, is being offered to people who are at the highest risk of getting gonorrhea.

This includes gay and bisexual men who have recently had multiple sexual partners and another bacterial STI within the last year. This new program is expected to protect thousands of people and save the NHS over £7.9 million in the next decade.

Gonorrhea Cases Also Rising In The US

Gonorrhea is also increasing in the US, with the 2025 data from the Centers for Disease Control and Prevention showing that reported cases of gonorrhea, chlamydia, and syphilis have climbed by nearly 90 per cent since 2004. In 2023 alone, the country recorded more than 2.4 million cases of sexually transmitted infections.

The United States Food and Drug Administration (FDA) in December last year approved two new oral antibiotics to treat gonorrhea: Zoliflodacin and Gepotidacin. These approvals represent the first entirely new gonorrhea treatments in more than three decades.

Retatrutide, Eli Lilly’s new weight-loss drug, is in the final stages of its clinical trial, and the results seem very promising, the drugmaker said on Thursday. In a news release, they disclosed that the brand-new drug helped people lose up to 30 per cent of their body weight, which is about 85 pounds. The results are on a par with bariatric surgery, which helps people shed approximately 25 to 35 per cent of their total body weight within one to two years. Doctors say that this is the largest weight loss ever witnessed in a medical trial. While Lilly has not yet filed for approval from the Food and Drug Administration, the pharma giant says that it expects to file this year.

What is Retatrutide?

Retatrutide is similar to drugs like Zepbound and Wegovy that mimic the GLP-1 hormone. Retatrutide, however, along with GLP-1, mimics glucagon as well, thereby working like a triple agonist. This is unlike Zepbound, which is a double agonist. Researchers said that they have witnessed the impact of semaglutide and tirzepatide. However, Retatrutide's results went beyond the current weight-loss drugs on the market.

Dr Shauna Levy, medical director of the Tulane Weight Loss Center, explained that the current GLP-1s are not good enough to induce weight loss in people dealing with severe obesity and those who have a BMI of 35. Bariatric surgery can provide the same, but it seems that Retatrutide will be far more effective for people living with a high BMI who are trying to achieve a healthy weight.

Read more: Meet Retatrutide: The Unapproved Cousin Of Ozempic That Supports Weight Loss Differently

Retatrutide's results

Retatrutide was in the third phase of its trials involving 2,300 obese or overweight participants. While the full results have not yet been released in a medical journal, participants who took the highest dose of the drug lost 28 per cent of their body weight, approximately 70 pounds. Furthermore, nearly half of the participants lost over 30 per cent of their body weight. The trial continued for 80 weeks, and a small group of severely obese patients took the drug for 104 weeks and lost about 85 pounds on average. Alternatively, patients who took high doses of Zepbound lost around 21 per cent of their body weight in 72 weeks. Wegovy users lost about 15 per cent of their weight in 68 weeks.

What were the side effects of Retatrutide?

On the downside, there were some side effects too. Retatrutide users experienced the following side effects:

1. Diarrhoea
2. Nausea
3. Constipation
4. Urinary tract infections
5. Uncomfortable skin sensations

These have, however, been seen with GLP-1 drugs.

New weight-loss drug coming soon?

Retatrutide might be the next big weight-loss drug set to hit the market soon. It aims to maximise weight-loss results with fewer side effects for users. If approved, it could be helpful for patients who are struggling to lose weight on the current versions of GLP-1 drugs.